195 related articles for article (PubMed ID: 25164277)
1. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
Cariou B; Staels B
Expert Opin Investig Drugs; 2014 Oct; 23(10):1441-8. PubMed ID: 25164277
[TBL] [Abstract][Full Text] [Related]
2. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
[TBL] [Abstract][Full Text] [Related]
3. The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.
Hanf R; Millatt LJ; Cariou B; Noel B; Rigou G; Delataille P; Daix V; Hum DW; Staels B
Diab Vasc Dis Res; 2014 Nov; 11(6):440-7. PubMed ID: 25212694
[TBL] [Abstract][Full Text] [Related]
4. Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.
Cariou B; Hanf R; Lambert-Porcheron S; Zaïr Y; Sauvinet V; Noël B; Flet L; Vidal H; Staels B; Laville M
Diabetes Care; 2013 Oct; 36(10):2923-30. PubMed ID: 23715754
[TBL] [Abstract][Full Text] [Related]
5. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
[No Abstract] [Full Text] [Related]
6. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism.
Cariou B; Zaïr Y; Staels B; Bruckert E
Diabetes Care; 2011 Sep; 34(9):2008-14. PubMed ID: 21816979
[TBL] [Abstract][Full Text] [Related]
7. Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.
Liu ZM; Hu M; Chan P; Tomlinson B
Expert Opin Investig Drugs; 2015 May; 24(5):611-21. PubMed ID: 25604802
[TBL] [Abstract][Full Text] [Related]
8. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Sahebkar A; Chew GT; Watts GF
Expert Opin Pharmacother; 2014 Mar; 15(4):493-503. PubMed ID: 24428677
[TBL] [Abstract][Full Text] [Related]
9. The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model.
Liu L; Liu C; Zhao M; Zhang Q; Lu Y; Liu P; Yang H; Yang J; Chen X; Yao Y
PLoS One; 2020; 15(12):e0243911. PubMed ID: 33326461
[TBL] [Abstract][Full Text] [Related]
10. Nuclear control of inflammation and fibrosis in nonalcoholic steatohepatitis: therapeutic potential of dual peroxisome proliferator-activated receptor alpha/delta agonism.
Quintero P; Arrese M
Hepatology; 2013 Dec; 58(6):1881-4. PubMed ID: 23787705
[No Abstract] [Full Text] [Related]
11. Design, synthesis, and biological evaluation of novel dual PPARα/δ agonists for the treatment of T2DM.
Ren Q; Deng L; Zhou Z; Wang X; Hu L; Xie R; Li Z
Bioorg Chem; 2020 Aug; 101():103963. PubMed ID: 32480174
[TBL] [Abstract][Full Text] [Related]
12. Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis.
Zhou Z; Deng L; Hu L; Ren Q; Cai Z; Wang B; Li Z; Zhang L
Eur J Pharmacol; 2020 Sep; 882():173300. PubMed ID: 32592770
[TBL] [Abstract][Full Text] [Related]
13. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
14. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
Evans JL; Lin JJ; Goldfine ID
Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
[TBL] [Abstract][Full Text] [Related]
15. The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
Li PP; Shan S; Chen YT; Ning ZQ; Sun SJ; Liu Q; Lu XP; Xie MZ; Shen ZF
Br J Pharmacol; 2006 Jul; 148(5):610-8. PubMed ID: 16751799
[TBL] [Abstract][Full Text] [Related]
16. [Treatment Options in Non-alcoholic Fatty Liver Disease].
Kim W
Korean J Gastroenterol; 2017 Jun; 69(6):353-358. PubMed ID: 28637104
[TBL] [Abstract][Full Text] [Related]
17. Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha/delta activation and increased mitochondrial fatty acid oxidation.
Løvås K; Røst TH; Skorve J; Ulvik RJ; Gudbrandsen OA; Bohov P; Wensaas AJ; Rustan AC; Berge RK; Husebye ES
Diabetes Obes Metab; 2009 Apr; 11(4):304-14. PubMed ID: 19267708
[TBL] [Abstract][Full Text] [Related]
18. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
19. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
20. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
